CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 855 enrolled
Drug / intervention
Oxybutynin (Oxytrol, BAY839380)drug
Likely dose
Oxybutynin (Oxytrol, BAY839380) 3.9 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04534491
NCT04534491Phase 3Completed

An Oxytrol Transdermal System Actual Use Study (Consumer Trial of Oxytrol, Control)

Bayer·interventional·Posted Sep 1, 2020·Updated Oct 20, 2020

In Brief

A Phase 3 clinical trial evaluating Oxybutynin (Oxytrol, BAY839380) for Overactive Bladder. Completed, enrolled 855 participants across 1 site.

Detailed Summary

With this study researchers want to gather information about the consumer use behavior of Oxytrol in a simulated setting in which the medicine is sold directly to a consumer without a prescription from a healthcare professional. An area of focus was on the potential benefits of an over-the-counter status for Oxytrol and on the ongoing use behavior of the consumers. Oxytrol is a thin, flexible, clear patch that is indicated for the treatment of overactive bladder a disease characterized by a collection of symptoms, including urinary frequency, urgency, and urge incontinence. The adhesive patch is placed on the skin to deliver Oxytrol through the skin into the bloodstream.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 1, 2020
Enrollment StartMay 25, 2010
Primary CompletionJun 22, 2011
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 5.8 years ago

Interventions

Oxybutynin (Oxytrol, BAY839380)drug

Oxybutynin transdermal patch, 3.9 mg daily (Oxytrol Transdermal System)